Back to top

RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)

In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $5.00. The compa...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pyxis Oncology, Inc. (PYXS)